[5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-1,3-oxazol-4-yl]-(1,3-dihydroisoindol-2-yl)methanone | 871080-12-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: [5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-1,3-oxazol-4-yl]-(1,3-dihydroisoindol-2-yl)methanone
• CAS: 871080-12-5
• 化学式: C₂₅H₂₁F₃N₄O₃
• 分子量: 482.462
• InChiKey: YXFRVNROZDVSNM-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  8-Methoxy-2-(trifluoromethyl)quinoline-5-carbonyl chloride 在 劳森试剂 、 盐酸 、 水 、 双(三甲基硅烷基)氨基钾 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 [5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-1,3-oxazol-4-yl]-(1,3-dihydroisoindol-2-yl)methanone
  参考文献：
  名称：

  Discovery of oral and inhaled PDE4 inhibitors

  摘要：

  The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.056

文献信息

• [EN] SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS<br/>[FR] 2-QUINOLYLE-OXAZOLES SUBSTITUÉS UTILES COMME INHIBITEURS DU PDE4
  申请人：SCHERING CORP

  公开号：WO2005116009A1

  公开（公告）日：2005-12-08

  The invention claims compounds of the: (formula I); wherein: (formula II) is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18R19; R3 and R4 H, alkyl, hydroxyalkyl or -C(O)Oalkyl; R5 and R6 are H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, -CH2F, -CHF2, -CF3, -C(O)OH or -C(O)Oalkyl; R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or -CH2-C(O)-O-alkyl; and R8 comprises alkyl, heteroaryl, phenyl or cycloalkyl, or heterocycloalkyl, all optionally substituted, or a cycloalkyl- or heterocycloalkyl-substituted amide; or R7 and R8 and the nitrogen to which they are attached together form an optionally substituted ring; and the remaining variables are as defined in the specification. Also claimed are pharmaceutical compositions, the use of the compounds as PDE4 inhibitors, and combinations with other actives.

  该发明声明了以下化合物：(化学式I)；其中：(化学式II)是一种5-成员杂环芳基；X为S或O；R1为H，烷基，环烷基，环烷基烷基，-CH2F，-CHF2，-CF3，-C(O)烷基或-C(O)NR18R19；R3和R4为H，烷基，羟基烷基或-C(O)O烷基；R5和R6为H，烷基，羟基烷基，烷氧基烷基，巯基烷基，-CH2F，-CHF2，-CF3，-C(O)OH或-C(O)O烷基；R7为H，烷基，烯基，羟基烷基，环烷基，烷氧基烷基，氨基烷基，(R17-苯基)烷基或-CH2-C(O)-O-烷基；R8包括烷基，杂环芳基，苯基或环烷基，或杂环烷基，均可选择性取代，或环烷基或杂环烷基取代的酰胺；或R7和R8及它们附着的氮一起形成一个可选择性取代的环；其余变量如规范中所定义。还声明了药物组合物，将这些化合物用作PDE4抑制剂，并与其他活性物质组合使用。
• US7511062B2
  申请人：——

  公开号：US7511062B2

  公开（公告）日：2009-03-31
• Discovery of oral and inhaled PDE4 inhibitors
  作者：Pauline C. Ting、Joe F. Lee、Rongze Kuang、Jianhua Cao、Danlin Gu、Ying Huang、Zhidan Liu、Robert G. Aslanian、Kung-I. Feng、Daniel Prelusky、James Lamca、Aileen House、Jonathan E. Phillips、Peng Wang、Ping Wu、Daniel Lundell、Richard W. Chapman、Chander S. Celly

  DOI：10.1016/j.bmcl.2013.08.056

  日期：2013.10

  The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed. (C) 2013 Elsevier Ltd. All rights reserved.